Ana Maciá-Casas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ana Maciá-Casas has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Roncero
Department of Health Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain
2 shared publications - Carmen Martin Gomez
Department of Psychiatry, University of Salamanca, Salamanca, Spain
2 shared publications - Jesus Perez
Department of Psychiatry, University of Salamanca, Salamanca, Spain
2 shared publications - Armando González-Sánchez
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Virgen de la Vega, 10 ª Planta, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain
1 shared publication - Belen Refoyo Matellan
Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
1 shared publication - Belén García-Berrocal
Department of Clinical Biochemistry, University Hospital of Salamanca, 37007 Salamanca, Spain
1 shared publication
Latest Publications
- Open Access
- 24 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e74408
Clinical utility of early intervention including the 5-Step Precision Medicine (5SPM) method in first-episode psychosis (the CLUMP project): Protocol for a cohort study with nested economic and process evaluations (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Psychotic disorders, such as schizophrenia, present a significant challenge to healthcare systems due to their high disability rates and treatment costs. With discontinuation rates for antipsychotics reaching over 40% in the first year and 80% after three years, it is crucial to tailor antipsychotic selection and dosing early in treatment. Personalised precision psychiatry, underpinned by pharmacogenetics, holds considerable potential in individualising antipsychotic treatment for patients with first-episode psychosis. The internationally pioneering method called 5SPM (5-Step Precision Medicine) lets the application of pharmacogenetics to clinical practice. The recently launched PRevention and early INTervention in mental health (PRINT) programme in Salamanca, Spain, integrates this method to enhance early intervention for adolescents and young people with first-episode psychosis. Objective: The CLinical Utility of early intervention including the 5-Step Precision Medicine (5SPM) Method in first-episode Psychosis (CLUMP) project aims to explore whether an early intervention model of personalised precision psychiatry, including pharmacogenetics, improves adherence to antipsychotic medicines and, therefore, clinical and functional outcomes in young people suffering from the first episode of a psychotic illness. Methods: To achieve our objectives, we shall compare adherence to the first prescribed antipsychotic medication and clinical and functional outcomes between patients with first-episode psychosis. We shall compare two cohorts: Cohort one will receive the recently introduced PRINT programme, including the 5-Step Precision Medicine (5SPM) method and cohort two would have received the standard care provided by mental health services before the PRINT programme implementation. The primary outcome to measure treatment adherence will be all-cause discontinuation proportions during one-year follow-up. Secondary outcome measures will include pragmatic efficacy, tolerability, and functional outcome measures. For additional comparative purposes, we shall analyse environmental, clinical and pharmacogenetic information of patients with psychotic disorders of more than five years of evolution and with other mental disorders, whose data are currently stored, and ethically approved for research use. A total of 300 patients will be included in the study. Analyses will include descriptive statistics, comparison tests, Kaplan-Meier survival curves, multivariate log-rank tests, qualitative analysis, and cost-benefit evaluation, among others. Results: Ethics approval was obtained in June 2023. Recruitment for the CLUMP project began in January 2025, and enrollment for Cohort 1 will continue until May 2026. All data collection is expected to be completed by June 2027. Data analyses are estimated to take approximately six months. The project is scheduled to conclude on December, 2027. Conclusions: The CLUMP project is set to provide the first clear blueprint for implementing and evaluating the impact of personalised precision psychiatry based on pharmacogenetics in the context of early intervention programmes for the benefit of young people suffering from the first episode of a severe mental illness, such as schizophrenia. Clinical Trial: ClinicalTrials.gov NCT06453174; https://clinicaltrials.gov/study/NCT06453174
- 24 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e74408
Open AccessClinical utility of early intervention including the 5-Step Precision Medicine (5SPM) method in first-episode psychosis (the CLUMP project): Protocol for a cohort study with nested economic and process evaluations (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Psychotic disorders, such as schizophrenia, present a significant challenge to healthcare systems due to their high disability rates and treatment costs. With discontinuation rates for antipsychotics reaching over 40% in the first year and 80% after three years, it is crucial to tailor antipsychotic selection and dosing early in treatment. Personalised precision psychiatry, underpinned by pharmacogenetics, holds considerable potential in individualising antipsychotic treatment for patients with first-episode psychosis. The internationally pioneering method called 5SPM (5-Step Precision Medicine) lets the application of pharmacogenetics to clinical practice. The recently launched PRevention and early INTervention in mental health (PRINT) programme in Salamanca, Spain, integrates this method to enhance early intervention for adolescents and young people with first-episode psychosis. Objective: The CLinical Utility of early intervention including the 5-Step Precision Medicine (5SPM) Method in first-episode Psychosis (CLUMP) project aims to explore whether an early intervention model of personalised precision psychiatry, including pharmacogenetics, improves adherence to antipsychotic medicines and, therefore, clinical and functional outcomes in young people suffering from the first episode of a psychotic illness. Methods: To achieve our objectives, we shall compare adherence to the first prescribed antipsychotic medication and clinical and functional outcomes between patients with first-episode psychosis. We shall compare two cohorts: Cohort one will receive the recently introduced PRINT programme, including the 5-Step Precision Medicine (5SPM) method and cohort two would have received the standard care provided by mental health services before the PRINT programme implementation. The primary outcome to measure treatment adherence will be all-cause discontinuation proportions during one-year follow-up. Secondary outcome measures will include pragmatic efficacy, tolerability, and functional outcome measures. For additional comparative purposes, we shall analyse environmental, clinical and pharmacogenetic information of patients with psychotic disorders of more than five years of evolution and with other mental disorders, whose data are currently stored, and ethically approved for research use. A total of 300 patients will be included in the study. Analyses will include descriptive statistics, comparison tests, Kaplan-Meier survival curves, multivariate log-rank tests, qualitative analysis, and cost-benefit evaluation, among others. Results: Ethics approval was obtained in June 2023. Recruitment for the CLUMP project began in January 2025, and enrollment for Cohort 1 will continue until May 2026. All data collection is expected to be completed by June 2027. Data analyses are estimated to take approximately six months. The project is scheduled to conclude on December, 2027. Conclusions: The CLUMP project is set to provide the first clear blueprint for implementing and evaluating the impact of personalised precision psychiatry based on pharmacogenetics in the context of early intervention programmes for the benefit of young people suffering from the first episode of a severe mental illness, such as schizophrenia. Clinical Trial: ClinicalTrials.gov NCT06453174; https://clinicaltrials.gov/study/NCT06453174
- Open Access
- 9 May 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (10) , 977
Post-Pandemic Evolution of Suicide Risk in Children and Adolescents Attending a General Hospital Accident and Emergency Department
Background: Lockdowns and other health protective measures, such as social distancing, imposed during the COVID-19 pandemic nurtured unprecedented levels of stress and social isolation around the world. This scenario triggered an increase in suicide thoughts and self-harm behaviours among children and young people. However, the longer-term impact of the pandemic on children’s and adolescents’ mental health, especially with regard to self-harm, is still to be fully discovered. Methods: We carried out a retrospective study where we collected data related to suicide ideation and self-harm behaviours in all patients aged under 18 that required on-call psychiatric services at the General Hospital Accident and Emergency (A&E) department in Salamanca, Spain, during 2019 (pre-pandemic) and in both 2021 and 2022 to capture possible variation at different time points during the post-pandemic period. Results: A total of 316 patients aged under 18 were seen by on-call psychiatric services at the A&E department during the three time periods: 78 in 2019, 98 in 2021 and 140 in 2022. The mean age was 15.12 (SD 2.25) and females represented more than twice the number of males each year. More than half of all patients assessed during 2022 disclosed suicide thoughts, whilst in 2019, it was near 25%. This increase in suicide ideation rates was more marked among females (X2 = 15.127; p = 0.001), those aged over 15 (X2 = 16.437; p < 0.001) and/or those with a previous history of mental health problems (X2 = 17.823; p < 0.001). We identified an increase in the proportion of males with suicide ideas, especially between 2021 and 2022 (X2 = 8.396; p = 0.015). Conclusions: Our study suggests that children’s and adolescents’ demand for urgent mental healthcare and their clinical presentations in A&E departments with suicide thoughts and/or self-injuries do not seem to be declining after the pandemic but increasing over time. More research is warranted to understand possible factors involved in this sustained upward trend.
- 9 May 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (10) , 977
Open AccessPost-Pandemic Evolution of Suicide Risk in Children and Adolescents Attending a General Hospital Accident and Emergency Department
Background: Lockdowns and other health protective measures, such as social distancing, imposed during the COVID-19 pandemic nurtured unprecedented levels of stress and social isolation around the world. This scenario triggered an increase in suicide thoughts and self-harm behaviours among children and young people. However, the longer-term impact of the pandemic on children’s and adolescents’ mental health, especially with regard to self-harm, is still to be fully discovered. Methods: We carried out a retrospective study where we collected data related to suicide ideation and self-harm behaviours in all patients aged under 18 that required on-call psychiatric services at the General Hospital Accident and Emergency (A&E) department in Salamanca, Spain, during 2019 (pre-pandemic) and in both 2021 and 2022 to capture possible variation at different time points during the post-pandemic period. Results: A total of 316 patients aged under 18 were seen by on-call psychiatric services at the A&E department during the three time periods: 78 in 2019, 98 in 2021 and 140 in 2022. The mean age was 15.12 (SD 2.25) and females represented more than twice the number of males each year. More than half of all patients assessed during 2022 disclosed suicide thoughts, whilst in 2019, it was near 25%. This increase in suicide ideation rates was more marked among females (X2 = 15.127; p = 0.001), those aged over 15 (X2 = 16.437; p < 0.001) and/or those with a previous history of mental health problems (X2 = 17.823; p < 0.001). We identified an increase in the proportion of males with suicide ideas, especially between 2021 and 2022 (X2 = 8.396; p = 0.015). Conclusions: Our study suggests that children’s and adolescents’ demand for urgent mental healthcare and their clinical presentations in A&E departments with suicide thoughts and/or self-injuries do not seem to be declining after the pandemic but increasing over time. More research is warranted to understand possible factors involved in this sustained upward trend.
- Open Access
- 25 February 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (5) , 2712
Impact on Sleep Quality, Mood, Anxiety, and Personal Satisfaction of Doctors Assigned to COVID-19 Units
The SARS-CoV-2 health emergency has led to a restructuring of health care systems and the reassignment of medical specialists from their usual duties to attend COVID-19 patients. The aim of this paper is to describe the levels of insomnia, anxiety, depression, and the impact on quality of life of doctors who were on the frontline of COVID-19 during the first two waves of the pandemic. Self-report surveys were conducted on said physicians during both waves, with 83 and 61 responses in the first and second waves, respectively. The reported presence of insomnia was frequent (71.8%), although it decreased in the second survey. Anxiety was moderate, decreasing from 57.1% to 43.1% between measurements. Overall, depression rates decreased between the two surveys. Substance use was found to have an indirect correlation with personal and professional satisfaction. In the light of the unforeseeable evolution of the pandemic and the medium- to long-term repercussions on professionals, we believe the adaptation of health resources is crucial to meet the new unpredictable mental health needs of this group.
- 25 February 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (5) , 2712
Open AccessImpact on Sleep Quality, Mood, Anxiety, and Personal Satisfaction of Doctors Assigned to COVID-19 Units
The SARS-CoV-2 health emergency has led to a restructuring of health care systems and the reassignment of medical specialists from their usual duties to attend COVID-19 patients. The aim of this paper is to describe the levels of insomnia, anxiety, depression, and the impact on quality of life of doctors who were on the frontline of COVID-19 during the first two waves of the pandemic. Self-report surveys were conducted on said physicians during both waves, with 83 and 61 responses in the first and second waves, respectively. The reported presence of insomnia was frequent (71.8%), although it decreased in the second survey. Anxiety was moderate, decreasing from 57.1% to 43.1% between measurements. Overall, depression rates decreased between the two surveys. Substance use was found to have an indirect correlation with personal and professional satisfaction. In the light of the unforeseeable evolution of the pandemic and the medium- to long-term repercussions on professionals, we believe the adaptation of health resources is crucial to meet the new unpredictable mental health needs of this group.